+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Unresectable Hepatocellular Carcinoma Market by Systemic Treatment, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5715740
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Unresectable Hepatocellular Carcinoma Market grew from USD 1.68 billion in 2023 to USD 1.90 billion in 2024. It is expected to continue growing at a CAGR of 13.38%, reaching USD 4.05 billion by 2030.

Unresectable Hepatocellular Carcinoma (uHCC) refers to liver cancer cases that cannot be surgically removed due to the tumor's size, location, or patient's overall health, creating a pressing need for alternative treatments. This underscores the necessity for therapeutic advancements such as immunotherapies, targeted therapies, and combination therapies. The application extends globally, impacting healthcare providers, pharmaceutical companies, and patients. The end-use scope covers hospitals, oncology centers, and research institutions. Market insights show that the rising incidence of liver diseases due to lifestyle factors, increased prevalence of chronic hepatitis infections, and improved diagnostics capabilities are significant growth drivers. The development of innovative drug delivery systems and personalized medicine are identified as key opportunities, particularly with the growing investment in R&D from pharma giants. However, high treatment costs, side effects of current therapies, and the complex nature of liver cancer treatment pose significant challenges. Additionally, regulatory hurdles and reimbursement issues often bottleneck the introduction of new therapies in certain markets. To overcome these limitations, fostering collaborations between biotechnology firms and academic institutions focusing on molecular research may lead to breakthroughs. Innovations in genetic profiling and biomarkers for early detection and tailored treatment plans are promising areas for business growth. Furthermore, expanding clinical trials in emerging markets can enhance patient access to new therapies and provide crucial data for broader application. A proactive approach, involving robust regulatory strategies and strategic partnerships with local healthcare providers, will be essential to navigate market complexities. In essence, the uHCC market is poised for growth driven by unmet medical needs and technological advancements, yet it requires strategic focus on overcoming financial and regulatory barriers to fully capitalize on opportunities.

Understanding Market Dynamics in the Unresectable Hepatocellular Carcinoma Market

The Unresectable Hepatocellular Carcinoma Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • High incidence rate of liver carcinoma
    • Increasing cases of liver cancer
    • Major application of chemotherapy
  • Market Restraints
    • Limited diagnosis of unresectable hepatocellular carcinoma
  • Market Opportunities
    • Advancements for new treatment and therapies
  • Market Challenges
    • Limited effects of current therapeutics

Exploring Porter’s Five Forces for the Unresectable Hepatocellular Carcinoma Market

Porter’s Five Forces framework further strengthens the insights of the Unresectable Hepatocellular Carcinoma Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Unresectable Hepatocellular Carcinoma Market

External macro-environmental factors deeply influence the performance of the Unresectable Hepatocellular Carcinoma Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Unresectable Hepatocellular Carcinoma Market

The Unresectable Hepatocellular Carcinoma Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Unresectable Hepatocellular Carcinoma Market

The Unresectable Hepatocellular Carcinoma Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Unresectable Hepatocellular Carcinoma Market

The Unresectable Hepatocellular Carcinoma Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Unresectable Hepatocellular Carcinoma Market, highlighting leading vendors and their innovative profiles. These include Astrazeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Chugai Pharmaceutical Co. Ltd, Eisai Co. Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Glaxosmithkline PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Pharmaxis Ltd, Sanofi S.A., and Sumitomo Dainippon Pharma Co., Ltd.

Market Segmentation & Coverage

This research report categorizes the Unresectable Hepatocellular Carcinoma Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Systemic Treatment
    • Chemotherapy
    • Immunotherapy
    • Molecularly Targeted Therapy
  • End User
    • Cancer Centers
    • Hospitals
    • Research institutes
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High incidence rate of liver carcinoma
5.1.1.2. Increasing cases of liver cancer
5.1.1.3. Major application of chemotherapy
5.1.2. Restraints
5.1.2.1. Limited diagnosis of unresectable hepatocellular carcinoma
5.1.3. Opportunities
5.1.3.1. Advancements for new treatment and therapies
5.1.4. Challenges
5.1.4.1. Limited effects of current therapeutics
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Unresectable Hepatocellular Carcinoma Market, by Systemic Treatment
6.1. Introduction
6.2. Chemotherapy
6.3. Immunotherapy
6.4. Molecularly Targeted Therapy
7. Unresectable Hepatocellular Carcinoma Market, by End User
7.1. Introduction
7.2. Cancer Centers
7.3. Hospitals
7.4. Research institutes
7.5. Specialty Clinics
8. Americas Unresectable Hepatocellular Carcinoma Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Unresectable Hepatocellular Carcinoma Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Unresectable Hepatocellular Carcinoma Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET RESEARCH PROCESS
FIGURE 2. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 9. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET DYNAMICS
TABLE 7. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MOLECULARLY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 19. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 21. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 22. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 23. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 24. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 26. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 30. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 31. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. AUSTRALIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 34. AUSTRALIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 36. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. INDIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 38. INDIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. INDONESIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 40. INDONESIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. JAPAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. JAPAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. MALAYSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 44. MALAYSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. PHILIPPINES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. PHILIPPINES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. SINGAPORE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. SINGAPORE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. SOUTH KOREA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 50. SOUTH KOREA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. TAIWAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 52. TAIWAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. THAILAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 54. THAILAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. VIETNAM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. VIETNAM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 63. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 65. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 73. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 79. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 81. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 89. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 93. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 99. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SHARE, BY KEY PLAYER, 2023
TABLE 103. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Unresectable Hepatocellular Carcinoma Market, which are profiled in this report, include:
  • Astrazeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chugai Pharmaceutical Co. Ltd
  • Eisai Co. Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Glaxosmithkline PLC
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pharmaxis Ltd
  • Sanofi S.A.
  • Sumitomo Dainippon Pharma Co., Ltd

Methodology

Loading
LOADING...

Table Information